European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading

MT Newswires Live11-17

European equities traded in the US as American depositary receipts kicked off the week tracking lower late Monday morning, declining 0.70% to 1,878.28 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and consumer goods company Unilever (UL), which advanced 1.6% and 1.1% respectively. They were followed by biotech firm BioNTech (BNTX) and brewing company Anheuser-Busch InBev (BUD), which increased 0.9% and 0.8% respectively.

The decliners from continental Europe were led by biopharmaceutical companies Cellectis (CLLS) and DBV Technologies (DBVT), which dropped 9.1% and 3.8% respectively. They were followed by petroleum refiner Equinor (EQNR) and telecommunications company Nokia (NOK), which lost 3.5% each.

The gainers from the UK were led by pharmaceutical company GSK (GSK) and tobacco company British American Tobacco (BTI), which rose 1.5% and 1.4% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and hospitality company InterContinental Hotels Group (IHG), which were up 1.3% and 0.8% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Bicycle Therapeutics (BCYC), which fell 4.1% and 3.7% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and mining company BHP Group (BHP), which were down 3.5% and 3.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment